Beacon Investment Advisors LLC purchased a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 165,556 shares of the biopharmaceutical company’s stock, valued at approximately $2,010,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Ocular Therapeutix by 26.3% during the fourth quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock valued at $140,523,000 after buying an additional 2,411,953 shares during the last quarter. Avoro Capital Advisors LLC raised its stake in Ocular Therapeutix by 38.5% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock worth $119,822,000 after acquiring an additional 2,850,000 shares during the last quarter. TCG Crossover Management LLC lifted its position in Ocular Therapeutix by 15.0% during the 3rd quarter. TCG Crossover Management LLC now owns 6,117,232 shares of the biopharmaceutical company’s stock worth $71,510,000 after acquiring an additional 798,084 shares during the period. Geode Capital Management LLC grew its stake in Ocular Therapeutix by 30.5% during the 4th quarter. Geode Capital Management LLC now owns 4,356,547 shares of the biopharmaceutical company’s stock valued at $52,896,000 after purchasing an additional 1,018,094 shares during the last quarter. Finally, State Street Corp grew its stake in Ocular Therapeutix by 21.3% during the 4th quarter. State Street Corp now owns 4,196,330 shares of the biopharmaceutical company’s stock valued at $50,943,000 after purchasing an additional 736,318 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors and hedge funds.
Ocular Therapeutix Price Performance
Shares of OCUL opened at $8.94 on Wednesday. The business’s 50-day moving average is $8.92 and its two-hundred day moving average is $9.95. The company has a market capitalization of $1.96 billion, a P/E ratio of -6.12 and a beta of 0.90. Ocular Therapeutix, Inc. has a fifty-two week low of $6.23 and a fifty-two week high of $16.44. The company has a debt-to-equity ratio of 0.12, a quick ratio of 14.73 and a current ratio of 14.81.
Insider Activity at Ocular Therapeutix
Analysts Set New Price Targets
A number of research analysts have recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $18.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, May 5th. William Blair reiterated an “outperform” rating on shares of Ocular Therapeutix in a research report on Monday, March 2nd. Wall Street Zen downgraded shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of Ocular Therapeutix in a research report on Monday, April 13th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $30.00 price objective on shares of Ocular Therapeutix in a research note on Wednesday, May 6th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Ocular Therapeutix presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.78.
View Our Latest Research Report on Ocular Therapeutix
Ocular Therapeutix Profile
Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.
The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.
Featured Articles
- Five stocks we like better than Ocular Therapeutix
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report).
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.
